{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T19:30:19Z","timestamp":1716579019726},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,9,18]],"date-time":"2011-09-18T00:00:00Z","timestamp":1316304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00262-011-1113-4","type":"journal-article","created":{"date-parts":[[2011,9,17]],"date-time":"2011-09-17T14:48:46Z","timestamp":1316270926000},"page":"397-407","source":"Crossref","is-referenced-by-count":12,"title":["Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2\/neu-tolerant mice"],"prefix":"10.1007","volume":"61","author":[{"given":"Angelos D.","family":"Gritzapis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis F.","family":"Voutsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin N.","family":"Baxevanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,18]]},"reference":[{"key":"1113_CR1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1084\/jem.193.11.1295","volume":"193","author":"MK Levings","year":"2001","unstructured":"Levings MK, Sangregorio R, Roncarolo MG (2001) Human CD25(+)CD4(+) t regulatory cells suppress na\u00efve and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295\u20131302","journal-title":"J Exp Med"},{"key":"1113_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.193.11.F41","volume":"193","author":"EM Shevach","year":"2001","unstructured":"Shevach EM (2001) Certified professionals: CD4(+)CD25(+) Suppressor T cells. J Exp Med 193:41\u201346","journal-title":"J Exp Med"},{"key":"1113_CR3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.192.9.1213","volume":"192","author":"H Jonuleit","year":"2000","unstructured":"Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin10-producing, non proliferating CD4(+) Tcells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213\u20131222","journal-title":"J Exp Med"},{"key":"1113_CR4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0952-7915(01)00273-4","volume":"13","author":"S Read","year":"2001","unstructured":"Read S, Powrie F (2001) CD4(+) regulatory T cells. Curr Opin Immunol 13:644\u2013649","journal-title":"Curr Opin Immunol"},{"key":"1113_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.coi.2004.01.010","volume":"16","author":"M Terabe","year":"2004","unstructured":"Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:157\u2013162","journal-title":"Curr Opin Immunol"},{"key":"1113_CR6","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00262-004-0540-x","volume":"53","author":"M Ahmad","year":"2004","unstructured":"Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression\/progression. Cancer Immunol Immunother 53:844\u2013854","journal-title":"Cancer Immunol Immunother"},{"key":"1113_CR7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942\u2013949","journal-title":"Nat Med"},{"key":"1113_CR8","first-page":"606","volume":"9","author":"AM Wolf","year":"2003","unstructured":"Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606\u2013612","journal-title":"Clin Cancer Res"},{"key":"1113_CR9","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","volume":"173","author":"M Viguier","year":"2004","unstructured":"Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444\u20131453","journal-title":"J Immunol"},{"key":"1113_CR10","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","volume":"168","author":"EY Woo","year":"2002","unstructured":"Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272\u20134276","journal-title":"J Immunol"},{"key":"1113_CR11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri821","volume":"2","author":"EM Shevach","year":"2002","unstructured":"Shevach EM (2002) CD4+CD25+suppressor T cells: more questions than answers. Nat Rev Immunol 2:389\u2013400","journal-title":"Nat Rev Immunol"},{"key":"1113_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2567.2002.01471.x","volume":"107","author":"A Gallimore","year":"2002","unstructured":"Gallimore A, Sakaguchi S (2002) Regulation of tumour immunity by CD25 +T cells. Immunology 107:5\u20139","journal-title":"Immunology"},{"key":"1113_CR13","first-page":"8643","volume":"61","author":"J Steitz","year":"2001","unstructured":"Steitz J, Br\u00fcck J, Lenz J, Knop J, T\u00fcting T (2001) Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61:8643\u20138646","journal-title":"Cancer Res"},{"key":"1113_CR14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.20042167","volume":"201","author":"AM Ercolini","year":"2005","unstructured":"Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591\u20131602","journal-title":"J Exp Med"},{"key":"1113_CR15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocyte associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823\u2013832","journal-title":"J Exp Med"},{"key":"1113_CR16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","volume":"299","author":"C Pasare","year":"2003","unstructured":"Pasare C, Medzhitov R (2003) Toll pathway dependent blockade of CD4+CD25+T cell mediated suppression by dendritic cells. Science 299:1033\u20131036","journal-title":"Science"},{"key":"1113_CR17","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211\u20135218","journal-title":"J Immunol"},{"key":"1113_CR18","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1158\/0008-5472.CAN-10-1736","volume":"70","author":"K Klages","year":"2010","unstructured":"Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T (2010) Selective Depletion of Foxp3\u00a0+\u00a0Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma. Cancer Res 70:7788\u20137799","journal-title":"Cancer Res"},{"key":"1113_CR19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737140.5.1.33","volume":"5","author":"JW Eklund","year":"2005","unstructured":"Eklund JW, Kuzel TM (2005) Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 5:33\u201338","journal-title":"Expert Rev Anticancer Ther"},{"key":"1113_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.177.1.84","volume":"177","author":"KL Knutson","year":"2006","unstructured":"Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML (2006) IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177:84\u201391","journal-title":"J Immunol"},{"key":"1113_CR21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","volume":"112","author":"MA Morse","year":"2008","unstructured":"Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610\u2013618","journal-title":"Blood"},{"key":"1113_CR22","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2007-06-094615","volume":"110","author":"MT Litzinger","year":"2007","unstructured":"Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C (2007) IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110:3192\u20133201","journal-title":"Blood"},{"key":"1113_CR23","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-09-2517","volume":"70","author":"AD Gritzapis","year":"2010","unstructured":"Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN (2010) Peptide vaccination breaks tolerance to HER-2\/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 70:2686\u20132696","journal-title":"Cancer Res"},{"key":"1113_CR24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4049\/jimmunol.181.1.146","volume":"181","author":"AD Gritzapis","year":"2008","unstructured":"Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN (2008) Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2\/neu with potent antitumor properties. J Immunol 181:146\u2013154","journal-title":"J Immunol"},{"key":"1113_CR25","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-05-4018","volume":"66","author":"AD Gritzapis","year":"2006","unstructured":"Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN (2006) Vaccination with human HER-2\/neu (435\u2013443) CTL peptide induces effective antitumor immunity against HER-2\/neu-expressing tumor cells in vivo. Cancer Res 66:5452\u20135460","journal-title":"Cancer Res"},{"key":"1113_CR26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","volume":"116","author":"SA Quezada","year":"2006","unstructured":"Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116:1935\u20131945","journal-title":"J Clin Invest"},{"key":"1113_CR27","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/ijc.22936","volume":"121","author":"IF Voutsas","year":"2007","unstructured":"Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN (2007) Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2\/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121:2031\u20132041","journal-title":"Int J Cancer"},{"key":"1113_CR28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/14712598.2010.482207","volume":"10","author":"TL Whiteside","year":"2010","unstructured":"Whiteside TL (2010) Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10:1019\u20131035","journal-title":"Expert Opin Biol Ther"},{"key":"1113_CR29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20050940","volume":"202","author":"K Ko","year":"2005","unstructured":"Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells. J Exp Med 202:885\u2013891","journal-title":"J Exp Med"},{"key":"1113_CR30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00262-002-0313-3","volume":"51","author":"N Labarri\u00e8re","year":"2002","unstructured":"Labarri\u00e8re N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dr\u00e9no B, Jotereau F (2002) Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 51:532\u2013538","journal-title":"Cancer Immunol Immunother"},{"key":"1113_CR31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","volume":"27","author":"P Salama","year":"2009","unstructured":"Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B (2009) Tumor-infiltrating FOXP3\u00a0+\u00a0T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186\u2013192","journal-title":"J Clin Oncol"},{"key":"1113_CR32","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","volume":"12","author":"N Hiraoka","year":"2006","unstructured":"Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3\u00a0+\u00a0regulatoryT cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423\u20135434","journal-title":"Clin Cancer Res"},{"key":"1113_CR33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1158\/1078-0432.CCR-06-2363","volume":"13","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S (2007) FOXP3\u00a0+\u00a0regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902\u2013911","journal-title":"Clin Cancer Res"},{"key":"1113_CR34","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","volume":"24","author":"AM Lee","year":"2006","unstructured":"Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ, Gribben JG, Lister TA, Goff LK (2006) Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24:5052\u20135059","journal-title":"J Clin Oncol"},{"key":"1113_CR35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-05-1886","volume":"12","author":"C Badoual","year":"2006","unstructured":"Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465\u2013472","journal-title":"Clin Cancer Res"},{"key":"1113_CR36","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1158\/1078-0432.CCR-07-1403","volume":"13","author":"L Strauss","year":"2007","unstructured":"Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL (2007) The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301\u20136311","journal-title":"Clin Cancer Res"},{"key":"1113_CR37","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/cncr.22282","volume":"107","author":"RP Petersen","year":"2006","unstructured":"Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr (2006) Tumor infiltrating Foxp3\u00a0+\u00a0regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866\u20132872","journal-title":"Cancer"},{"key":"1113_CR38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","volume":"58","author":"N Leffers","year":"2009","unstructured":"Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58:449\u2013459","journal-title":"Cancer Immunol Immunother"},{"key":"1113_CR39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4049\/jimmunol.178.1.320","volume":"178","author":"L Strauss","year":"2007","unstructured":"Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A (2007) Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178:320\u2013329","journal-title":"J Immunol"},{"key":"1113_CR40","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","volume":"28","author":"HM Prince","year":"2010","unstructured":"Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A (2010) Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28:1870\u20131877","journal-title":"J Clin Oncol"},{"key":"1113_CR41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrclinonc.2010.105","volume":"7","author":"EM Kadin","year":"2010","unstructured":"Kadin EM, Vonderheid EC (2010) Targeted therapies: Denileukin diftitox\u2014a step towards a \u2018magic bullet\u2019 for CTCL. Nat Rev Clin Oncol 7:430\u2013432","journal-title":"Nat Rev Clin Oncol"},{"key":"1113_CR42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-6-12","volume":"6","author":"MA Rasku","year":"2008","unstructured":"Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J (2008) Transient T cell depletion causes regression of melanoma metastases. J Transl Med 6:12. doi: 10.1186\/1479-5876-6-12","journal-title":"J Transl Med"},{"key":"1113_CR43","doi-asserted-by":"crossref","unstructured":"Chesney J, Rasku MA, Klarer AC, Miller DM, Telang S (2011) Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. ASCO Annual Meeting J Clin Oncol 29:2011 (suppl; abstr 2507)","DOI":"10.1200\/jco.2011.29.15_suppl.2507"},{"key":"1113_CR44","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","volume":"115","author":"J Dannull","year":"2005","unstructured":"Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623\u20133633","journal-title":"J Clin Invest"},{"key":"1113_CR45","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.4049\/jimmunol.176.5.2722","volume":"176","author":"J Taieb","year":"2006","unstructured":"Taieb J, Chaput N, Schartz N, Roux S, Novault S, M\u00e9nard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-J\u00e8ze G et al (2006) Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722\u20132729","journal-title":"J Immunol"},{"key":"1113_CR46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2009.04939.x","volume":"1174","author":"AJ Rech","year":"2009","unstructured":"Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99\u2013106","journal-title":"Ann N Y Acad Sci"},{"key":"1113_CR47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/08830185.2010.489658","volume":"29","author":"D Martorelli","year":"2009","unstructured":"Martorelli D, Muraro E, Merlo A, Turrini R, Rosato A, Dolcetti R (2009) Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 29:371\u2013402","journal-title":"Int Rev Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-011-1113-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1113-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T17:24:42Z","timestamp":1686331482000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1113-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,18]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1113-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,18]]}}}